Sentinel lymph node biopsy with Magtrace®

Performing a sentinel lymph node biopsy (SLNB) to determine whether cancer cells have migrated requires reliable and accurate marking of the sentinel nodes. Not all lymph node mapping agents offer this.

Despite the advantages of SLNB over more invasive procedures such as axillary lymph node dissection (ALND), the conventional method involves injecting a radioactive tracer with blue dye, then localizing the lymph nodes using a gamma probe. This means that only hospitals with nuclear medicine are able to give patients the ‘gold standard’ of care.

With Magtrace®, there’s another way.

1. Limited supply
   Radioactive materials are made in just a handful of nuclear facilities worldwide, limiting access to this treatment around the world.
   
2. Product decay
   Radioisotope decays so quickly that it has to be supplied to hospitals weekly. Patients must be injected close to surgery, putting a burden on hospital scheduling.
   
3. Handling and costs
   Due to the costs of supply and handling of radioisotopes, often only patients located near to large specialist cancer centres can access the ‘gold standard’.

The Magtrace® lymphatic tracer has proven to be effective in numerous clinical trials, involving more than 5,000 patients across Europe and North America.

The tiny particles in the Magtrace® lymphatic tracer are able to quickly pass through the lymphatic system, following the same path a spreading cancer cell would take. The magnetic liquid works in as little as 20 minutes and is still detectable many days afterwardsÅ. This offers unrivalled flexibility for both physicians and patients, so injection can be timed to coincide with a planned hospital visit or when the patient is in the operating room. Magtrace® has now been used in over 65,000 patients, in more than 600 hospitals across upwards of 40 countries.

Magtrace® offers unrivalled scheduling flexibility and can be injected weeks before surgery or under anesthesia in the OR. If injected days before surgery, Magtrace® has been noted to be less painful than radioactive isotope†.

Magtrace® moves rapidly through the lymphatic system. The 60nm particles are optimized to be mechanically filtered by the sentinel lymph nodes and not pass to higher-echelon nodes.

Magtrace® has a 99.3% detection rate, finds an average of 2.4 nodes per patient and is non-inferior to radioisotope and blue dye*. It also discolors the node, offering the additional benefit of visual backup.

The SentimagIC trial demonstrated Magtrace® to be non-inferior when compared to the blue dye and technetium dual tracer.

• 40 + clinical trials
• 8,000+ patients in total
• 100+ publications
• 5 meta analyses

Give your patients a better standard of breast cancer surgery without the need for wires and radioactivity.

→ Set up a no cost, no commitment evaluation today.